A nurse is caring for a patient with rheumatoid arthritis who is experiencing a flare-up. The patient has received corticosteroid injections in the past but is concerned about potential side effects. Which of the following side effects should the nurse inform the patient to monitor for when using glucocorticoids?

Rationale:

A. Epistaxis, or nosebleeds, is a manifestation of ongoing bleeding due to low platelet counts. While mild bleeding may be expected in ITP, its presence does not indicate improvement. Clinicians monitor for a reduction or cessation of bleeding episodes as a sign of recovery.

B. Iron levels are not a primary measure of ITP improvement. Although chronic bleeding in ITP can eventually lead to iron deficiency, a change in iron does not reflect platelet recovery or improved hemostasis. Monitoring iron may be part of supportive care but is not an indicator of treatment success.

C. Platelet count is the most objective measure of recovery in ITP. Normal platelet levels indicate that the immune-mediated destruction of platelets has diminished or that treatment has successfully stimulated platelet production. Achieving a count above 150,000/mm³ signifies a return to effective hemostasis, reducing the risk of spontaneous bleeding.

D. Petechiae are small, pinpoint hemorrhages on the skin caused by low platelet counts. A decrease in petechiae is a visible, clinical sign that bleeding tendencies are resolving and indicates improved platelet function. This complements laboratory monitoring by providing a real-time, observable measure of patient improvement.

E. Persistent bruising reflects ongoing thrombocytopenia and bleeding risk. If bruising does not improve, it suggests that treatment has not yet been effective, and further evaluation or therapy adjustments may be necessary.

Rationale:

A. Gastrointestinal upset is a common side effect of pyridostigmine, not an indicator of treatment effectiveness. While monitoring for adverse effects is important, diarrhea does not reflect whether the medication is improving muscle function.

B. Pyridostigmine enhances neuromuscular transmission, leading to reduced muscle fatigue. A patient reporting less fatigue during daily activities indicates the medication is working effectively.

C. Injection site discomfort is not related to the efficacy of pyridostigmine; it is a local adverse effect. Monitoring for pain is important for patient comfort, but it does not indicate treatment success.

D. Ptosis, dysarthria, and difficulty speaking are common symptoms in myasthenia gravis due to weak facial and respiratory muscles. Improvement in speech endurance reflects enhanced neuromuscular function, signaling effective therapy.

E. Pyridostigmine increases acetylcholine availability at the neuromuscular junction, improving skeletal muscle strength. Observable improvements in mobility or exercise tolerance indicate treatment effectiveness.

F. Respiratory muscles may be affected in myasthenia gravis, and pyridostigmine can enhance respiratory muscle strength, reducing dyspnea or respiratory compromise. This is a critical indicator of therapeutic effectiveness, especially to prevent myasthenic crisis.

G. While pyridostigmine can cause cholinergic side effects such as bradycardia, changes in heart rate are not an indicator of effectiveness. Heart rate monitoring is for safety and side effect management, not therapeutic assessment.